Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Just In
Phil Donahue, talk show pioneer and husband of Marlo Thomas died Sunday at age 88
Program
6 p.m. Monday on WRAL: Find out why millions of your tax dollars sent to 868 private and religious schools across NC
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Actinium Pharmaceuticals Inc
(NY:
ATNM
)
2.090
+0.270 (+14.84%)
Official Closing Price
Updated: 4:10 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Actinium Pharmaceuticals Inc
< Previous
1
2
Next >
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 18, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 09, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
August 07, 2024
From
The Schall Law Firm
Via
Business Wire
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
June 18, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and...
Via
Newsfile
Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
June 18, 2024
Via
AB Newswire
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
June 17, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first...
Via
Newsfile
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
June 17, 2024
Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin...
Via
FinancialNewsMedia
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
June 17, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
May 09, 2024
Via
AB Newswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
May 08, 2024
Via
AB Newswire
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
April 19, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
April 17, 2024
Via
AB Newswire
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
March 28, 2024
Via
AB Newswire
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial
March 27, 2024
Via
AB Newswire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
March 26, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
March 22, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
March 21, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
March 20, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) launches strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225)
March 14, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
February 22, 2023
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
February 22, 2023
– Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of...
Via
FinancialNewsMedia
Actinium Pharmaceuticals’ Shares Stay Bullish Ahead Of Expected Topline Phase 3 Data Release In Q4 ($ATNM)
December 12, 2022
Via
AB Newswire
Actinium Pharmaceuticals’ Shares Rally Ahead Of Topline Phase 3 Data Release; Update Expected By Year’s End ($ATNM)
December 08, 2022
Via
AB Newswire
Actinium Pharmaceuticals’ Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 Catalysts ($ATNM)
October 26, 2022
Via
AB Newswire
Actinium Pharmaceuticals’ Investor Update Puts Clinical Milestones And Potential Catalysts In The Crosshairs ($ATNM)
October 24, 2022
Via
AB Newswire
Actinium Pharmaceuticals Rally Takes Stock 62% Higher As Its Iomab-B Data Continues To Impress (NYSE AMERICAN: ATNM)
September 29, 2021
Via
AB Newswire
Exposures
Product Safety
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.